List/Grid Tag Archives: ch14.18
Discussing relapse treatments in the UK
Navigating a path through relapsed neuroblastoma is a challenge for parents regardless of geography. However, treatment following relapse is generally determined, at least in the first instance, by locally available options and prevailing attitudes which differ between countries, institutions, and even individual oncologists.
In 2011 Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), ...
Ethical Issues for Control-Arm Patients …
A thought-provoking article that recently appeared online in the Journal of Clinical Oncology, ahead of full publication. The paper entitled, Ethical Issues for Control-Arm Patients After Revelation of Benefits of Experimental Therapy: A Framework Modeled in Neuroblastoma, discusses the decision to offer ch14.18 immunotherapy to control-arm patients on the Children’s Oncology Group (COG) clinical ...
Paladin Labs in licensing agreement for APN311 (ch14.18)
Paladin Labs Inc. have entered into an exclusive licensing agreement with Apeiron Biologics AG for APN311, the ch14.18 chimeric monoclonal antibody currently in a SIOPEN Phase III clinical trial across Europe. The license grants Paladin rights to market and sell APN311 in Canada and parts of Africa.
See the associated press release for further details.
Court rules in favor of UK child seeking antibody treatment
Randomization to ch14.18 alone challenged, UK court rules in favor of child
The SIOPEN trial now accruing in 20 countries in Europe randomizes children to the antibody ch14.18 alone or ch14.18 with subcutaneous IL2. Part of this trial was amended after the March 2009 release of the Children’s Oncology Group early results showing 2-year event free survival of 66% with ch14.18, IL2, and GM-CSF ...
AACR 2011 ~ 102nd meeting
The American Association for Cancer Research (AACR) is the oldest and largest scientific organization in the world focused on every facet of cancer research. AACR was founded in 1907 by 11 physicians and scientists interested in research with the goal to “to further the investigation and spread the knowledge of cancer.” Since then, the AACR has grown to 33,000 members and publishes seven ...
New antibody trials in 2011
Antibodies for relapsed neuroblastoma
Given that recent studies such as COG-3973 [1] and others reveal that half or more of all children with high-risk neuroblastoma are refractory to induction or relapse, and that the majority worldwide never received antibodies as part of frontline treatment, there is currently a significant demand for access to antibody treatment after relapse.
Currently, the only ...
Antibodies and other bits
Big antibody news
The “third generation” humanized anti-GD2 antibody with protein fusion of IL2 to the antibody has completed Phase I and II clinical trials for melanoma and neuroblastoma, and is now ready for use in Phase III clinical trials. The license for hu14.18-IL2 was just acquired by a small biotech in Vienna called Apeiron. The license was acquired from Merck.
Apeiron’s press ...
Latest neuroblastoma related news
Neuroblastoma bits from November 2010
.
Excellent new review article on anti-GD2 antibodies
Just published by Yang and Sondel, this thorough review tracks the evolution of antibodies for neuroblastoma through three generations: murine, chimeric, and humanized, and explains the of mechanisms for tumor kill and results of all prior trials. The summary details all combinations with cytokines, modifications ...
Biggest news for neuroblastoma in a decade: ch14.18 plus GM-CSF and IL2
Rare news
A disease that afflicts only 350 children per year in the US (in the high-risk form) does not make headlines very often. But after the September 30, 2010 publication of the New England Journal of Medicine article revealing the results of the phase III chimeric antibody trial (ch14.18 given with two cytokines GM-CSF and IL2), neuroblastoma was all over the news including prime time national ...
New frontline high-risk neuroblastoma trial includes MIBG transplant
Pilot study: 131I-MIBG radiotherapy with chemotherapy after induction for newly diagnosed
Dr Greg Yanik (University of Michigan) presented preliminary results of the NANT (New Approaches to Neuroblastoma Therapy) NANT-2001-02 phase 2 MIBG + CEM (131I-MIBG radiotherapy with carboplatin, etoposide, and melphalan) stem cell transplant trial on June 23rd 2010 at the Advances in Neuroblastoma Research ...
